Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical stage pharmaceutical company. The Company is engaged in the research and development of light, radiation, sound and/or drug-activated small molecule compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Exceptional Value
View:
Post by leste3221 on Jan 07, 2025 9:48am

Exceptional Value

Theralase's product is significantly better than Merck's competing product, the acquisition price would reflect its superior value and market potential. Here's a breakdown:

  1. Exceptional Value of the Product: If Theralase's product outperforms Merck's by a wide margin, it could dominate the market, allowing Merck to:

    • Capture a larger market share.
    • Reduce R&D costs for its competing product.
    • Secure a long-term competitive advantage.
  2. Current Valuation: Theralase’s market cap (e.g., CAD 50–100M) and financial position would set the baseline for negotiations. However, the superior product's potential would justify a substantial premium.

  3. Industry Acquisition Multiples:

    • 5–10× revenues if the product is already commercialized.
    • 2–5× peak annual sales projections for products still in trials.

    If Theralase’s product has the potential to generate CAD 500M annually at its peak, Merck might reasonably pay CAD 1.5–3B, or even more, depending on competitive factors.

  4. Comparison to Similar Deals:

    • Merck paid $10.8B for Prometheus Biosciences in 2023 for a promising product pipeline.
    • Sanofi acquired Kadmon for $1.9B in 2021 for a product with strong future potential.

Estimated Price Range

Given the significant superiority of Theralase’s product, a reasonable acquisition price could be between CAD 1.5B and 3B

Comment by Alamir1111 on Jan 07, 2025 10:35am
500M as its peak that would roughly translate to 2000 patients treated yearly at 250000$ 
Comment by gojotv! on Jan 07, 2025 10:57am
I love how Big Pharma's plants come to this board to try to sway investors to agree to acquisition... You're not listening. TLT longs are't looking to be bought up by some international firm for pennies on the pennies on the Canadian (lower) dollar. We want our own, Canadian Big Pharma-Tech corporation to keep high-paying jobs here and to go keep oncology costs down, saving and even ...more  
Comment by chry200030 on Jan 07, 2025 11:02am
But a buyout for $200 per share U.S. I wouldn't sneeze at.  !!
Comment by gojotv! on Jan 07, 2025 11:09am
I'd hold out for $500 U.S.  The cost to the country of selling would just be too great. And remember, it's not just Ruvidar, it's Laser tech equipment, too! Such a variety of jobs to keep in Canada! The value of the cure for cancer? Hundreds of billions. The value of setting goals to motivate the youth to pursue their educations? Priceless. This could be Canada's century at ...more  
Comment by bmk211 on Jan 07, 2025 11:15am
Ruvidar and all of the technology/research discoverd through Theralase are definitely more valuable than the bladder cancer market.   There is no question.   We are talking about great results with 1 or 2 treatments limited by the clinical study being done with 100% safety.    Just think what will be improved and unlocked in the future.  CR rates will be much ...more  
Comment by Legit62 on Jan 07, 2025 11:22am
Great point but just imagine hitting the cancer when first diagnosed instead of after everything else fails treatment and all the wasted and painful time , costly treatments,side affects ETC
Comment by charlierock on Jan 07, 2025 12:45pm
$500 USgojo? I like your enthusiasm but cool your jets just a little. We haven't even seen a dollar yet and even though the data is world class, nothings a slam dunk being at the mercy of the FDA. This is high risk high reward and I'm making a bet with my share count in the six figures that TLT will be a success. If we're successful I think there will be joint ventures and an eventual ...more  
Comment by Alamir1111 on Jan 07, 2025 1:10pm
500 usd =717cdn that would get me 500 mil on my tfsa.i think cra  would make up new rules to get some of that $
Comment by bmk211 on Jan 07, 2025 11:11am
a $200 U.S.  is 70 billion dollar buyout if fully dilluted there are 350,000,000 shares. 
Comment by DeathXray33 on Jan 07, 2025 11:03am
"Irish vaccine plant"
Comment by Maxcitrac on Jan 07, 2025 11:25am
gojotv I fully agree, as Theralase Ruvidar data are getting better and better, more posters are coming on board and right away they are talking about selling Theralase to big pharma(acquisition). Dr LBiati was brought on board to sign a Joint Venture deal with a big pharma, not to sell Theralase to a big pharma. A joint venture deal will give Theralase the money needed to become a very big ...more  
Comment by Kayz88 on Jan 07, 2025 12:00pm
This is great - Can you post that on reddit? Possibly for /r/UndervaluedStonks/ I'm not against posting on Stockhouse, but this place is a vaccuum, we are all already on board, it'll be good if we can get new/more eyes on it. We all know and believe in the science and technology, we all have a valuation target in mind. We all do our own DD's (great DD's at that) - let's share ...more  
Comment by bmk211 on Jan 07, 2025 12:06pm
Would it be wrong for you to copy it and just add it to your post?  The user account doesn't have much activity on here 
Comment by Kayz88 on Jan 07, 2025 12:31pm
Someone else should do it. Wouldn't be good form for OP to keep adding to post with new info.  More than happy to create a new post after a few days.
Comment by bmk211 on Jan 07, 2025 2:11pm
true
Comment by Alamir1111 on Jan 07, 2025 2:46pm
Oh I know the feeling f twitter facebook genx  fda  government  hca  bp institutions reddit pumpers bashers who  sh penny flippers shorters  manipulaters etc the list goes on.
Comment by fecats on Jan 07, 2025 12:08pm
Leste3221,  Your numbers are spot on for tx for NMIBC.But there is no way that 1.5-2 B would take the whole package . Too much other stuff in the pipeline. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities